Gynecol Oncol

1. GITTO SB, Ihewulezi CJN, Powell DJ Jr
   Adoptive T cell therapy for ovarian cancer.
   Gynecol Oncol. 2024;186:77-84.
   

   >> Share

   
   
2. DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al
   Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
   Gynecol Oncol. 2024;186:69-76.
   

   >> Share

   
   
3. SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al
   Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.
   Gynecol Oncol. 2024;186:53-60.
   

   >> Share

   
   

   
   Int J Gynaecol Obstet

4. MIYAMOTO E, Yoshihara M, Iyoshi S, Mogi K, et al
   Factors affecting the long-term prognosis of patients in the AYA generation with epithelial ovarian cancer: A multicenter propensity score matching analysis.
   Int J Gynaecol Obstet. 2024 Apr 12. doi: 10.1002/ijgo.15479.
   

   >> Share

   
   

   
   Oncogene

5. CHEN H, Lee LJ, Vincent KM, Xu Z, et al
   Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.
   Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03026.
   

   >> Share

   
   

   
   PLoS One

6. CHEN Z, Wang C, Ding J, Yu T, et al
   Construction and analysis of competitive endogenous RNA networks and prognostic models associated with ovarian cancer based on the exoRBase database.
   PLoS One. 2024;19:e0291149.
   

   >> Share

   
   
7. MEHRA T, Lupatsch JE, Kossler T, Dedes K, et al
   Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
   PLoS One. 2024;19:e0301271.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share